» Articles » PMID: 34880314

A Proteomics Study Identifying Interactors of the FSHD2 Gene Product SMCHD1 Reveals RUVBL1-dependent DUX4 Repression

Overview
Journal Sci Rep
Specialty Science
Date 2021 Dec 9
PMID 34880314
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Structural Maintenance of Chromosomes Hinge Domain Containing 1 (SMCHD1) is a chromatin repressor, which is mutated in > 95% of Facioscapulohumeral dystrophy (FSHD) type 2 cases. In FSHD2, SMCHD1 mutations ultimately result in the presence of the cleavage stage transcription factor DUX4 in muscle cells due to a failure in epigenetic repression of the D4Z4 macrosatellite repeat on chromosome 4q, which contains the DUX4 locus. While binding of SMCHD1 to D4Z4 and its necessity to maintain a repressive D4Z4 chromatin structure in somatic cells are well documented, it is unclear how SMCHD1 is recruited to D4Z4, and how it exerts its repressive properties on chromatin. Here, we employ a quantitative proteomics approach to identify and characterize novel SMCHD1 interacting proteins, and assess their functionality in D4Z4 repression. We identify 28 robust SMCHD1 nuclear interactors, of which 12 are present in D4Z4 chromatin of myocytes. We demonstrate that loss of one of these SMCHD1 interacting proteins, RuvB-like 1 (RUVBL1), further derepresses DUX4 in FSHD myocytes. We also confirm the interaction of SMCHD1 with EZH inhibitory protein (EZHIP), a protein which prevents global H3K27me3 deposition by the Polycomb repressive complex PRC2, providing novel insights into the potential function of SMCHD1 in the repression of DUX4 in the early stages of embryogenesis. The SMCHD1 interactome outlined herein can thus provide further direction into research on the potential function of SMCHD1 at genomic loci where SMCHD1 is known to act, such as D4Z4 repeats, the inactive X chromosome, autosomal gene clusters, imprinted loci and telomeres.

Citing Articles

SMCHD1 has separable roles in chromatin architecture and gene silencing that could be targeted in disease.

Tapia Del Fierro A, den Hamer B, Benetti N, Jansz N, Chen K, Beck T Nat Commun. 2023; 14(1):5466.

PMID: 37749075 PMC: 10519958. DOI: 10.1038/s41467-023-40992-6.


Update on the Molecular Aspects and Methods Underlying the Complex Architecture of FSHD.

Caputo V, Megalizzi D, Fabrizio C, Termine A, Colantoni L, Caltagirone C Cells. 2022; 11(17).

PMID: 36078093 PMC: 9454908. DOI: 10.3390/cells11172687.

References
1.
Tassin A, Laoudj-Chenivesse D, Vanderplanck C, Barro M, Charron S, Ansseau E . DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?. J Cell Mol Med. 2012; 17(1):76-89. PMC: 3823138. DOI: 10.1111/j.1582-4934.2012.01647.x. View

2.
Dull T, Zufferey R, Kelly M, Mandel R, Nguyen M, Trono D . A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998; 72(11):8463-71. PMC: 110254. DOI: 10.1128/JVI.72.11.8463-8471.1998. View

3.
Hamanaka K, Sikrova D, Mitsuhashi S, Masuda H, Sekiguchi Y, Sugiyama A . Homozygous nonsense variant in associated with facioscapulohumeral muscular dystrophy. Neurology. 2020; 94(23):e2441-e2447. PMC: 7455367. DOI: 10.1212/WNL.0000000000009617. View

4.
Wilkie A . Many faces of SMCHD1. Nat Genet. 2017; 49(2):176-178. DOI: 10.1038/ng.3776. View

5.
Himeda C, Jones T, Virbasius C, Zhu L, Green M, Jones P . Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy. Mol Ther. 2018; 26(7):1797-1807. PMC: 6035737. DOI: 10.1016/j.ymthe.2018.04.019. View